Alexandria Real Estate Equities, Inc

Alexandria Real Estate Equities, Inc(ARE)股票分析

$41.500

-2.195 (-5.29%)收盤時

Loading chart…
最高
43.684
開盤
43.280
成交量加權均價
42.17
成交量
2.85M
市值
20.35B
最低
41.340
成交金額
120.34M
企業價值/稅息折舊攤銷前利潤(TTM)
11.67

Alexandria Real Estate Equities, Inc. is a life science real estate investment trust. The Company is an owner, operator and developer of collaborative life science, agricultural technology (agtech), and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The Company, through its venture capital platform, provides strategic capital to life science, agrifoodtech, climate innovation, and technology companies. Its tenants include multinational pharmaceutical companies; public and private biotechnology companies; life science product, service and medical device companies; digital health, technology, and agtech companies; academic and medical research institutions; United States government research agencies; non-profit organizations, and venture capital firms. It has a Labspace asset base predominantly concentrated in markets with barriers to entry.

AI 分析 of Alexandria Real Estate Equities, Inc (ARE)

賣出

Alexandria Real Estate Equities Inc is not a good buy right now due to significant financial instability and negative market sentiment. The current price is $45.51, with an RSI of 23.288 indicating the stock is oversold. Additionally, the stock has experienced a 38.39% decline over the past year, contrasting sharply with the S&P 500's 17.2% gain, suggesting a lack of investor confidence. The main risk is the company's high debt-to-equity ratio of 66.85%, which raises concerns about its financial health and ability to recover.

分析師評級(12)

上檔空間 +36.99%
買進
7 買進
5 持有
0 賣出
目前: 41.50
最低
41.00
平均
56.85
最高
67.00

BMO Capital

2026-10-12

目標價

$41

Market Perform

JPMorgan

2026-09-24

目標價

$56

減持

Evercore ISI

2026-09-21

目標價

$59

優於大盤

Baird

2026-08-24

目標價

$52

中性

BofA

2026-08-24

目標價

$55

中性

估值指標

Alexandria Real Estate Equities, Inc(ARE)目前預期本益比為 16.69,5 年平均預期本益比為 47.23。

預期本益比

合理
5 年均值 P/E
47.23
目前P/E
16.69
高估
82.91
低估
11.54

預期 EV/EBITDA

低估
5 年均值 EV/EBITDA
20.38
目前EV/EBITDA
11.67
高估
28.39
低估
12.38

預期股價營收比

低估
5 年均值 P/S
6.74
目前P/S
3.01
高估
9.59
低估
3.89

Alphio AI 對 ARE 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%ARE

$70.33

情境價格

基

基準

基準 · 50%ARE

$69.46

情境價格

悲

悲觀

悲觀 · 25%ARE

$59.44

情境價格

持有 ARE 的大戶

S

Stichting Pensioenfonds ABP

+ 持有ARE

+3.10%

3個月報酬率

C

Clal Financial Management Ltd

+ 持有ARE

-2.56%

3個月報酬率

Q

Quinn Opportunity Partners LLC

+ 持有ARE

-5.96%

3個月報酬率

C

CenterSquare Investment Management LLC

+ 持有ARE

-9.98%

3個月報酬率

ARE 常見問題 —— 由 Alphio AI 解答

Alexandria Real Estate Equities, Inc. is a life science real estate investment trust. The Company is an owner, operator and developer of collaborative life science, agricultural technology (agtech), and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The Company, through its venture capital platform, provides strategic capital to life science, agrifoodtech, climate innovation, and technology companies. Its tenants include multinational pharmaceutical companies; public and private biotechnology companies; life science product, service and medical device companies; digital health, technology, and agtech companies; academic and medical research institutions; United States government research agencies; non-profit organizations, and venture capital firms. It has a Labspace asset base predominantly concentrated in markets with barriers to entry. It operates in the Real Estate sector (REAL ESTATE INVESTMENT TRUSTS industry).

Alexandria Real Estate Equities Inc is not a good buy right now due to significant financial instability and negative market sentiment. The current price is $45.51, with an RSI of 23.288 indicating the stock is oversold. Additionally, the stock has experienced a 38.39% decline over the past year, contrasting sharply with the S&P 500's 17.2% gain, suggesting a lack of investor confidence. The main risk is the company's high debt-to-equity ratio of 66.85%, which raises concerns about its financial health and ability to recover.

12 analysts cover ARE: 7 rate it Buy, 5 Hold and 0 Sell. The average price target is 56.85.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易